[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hepatopancreatobiliary Surgery Institute of Gansu Province\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":128},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,74,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100617654","the-optimal-measurement-time-for-the-new-gallbladder-function-assessment-method-100617654",false,"NCT07321431","The Optimal Measurement Time for the New Gallbladder Function Assessment Method","The Optimal Measurement Time for the New Gallbladder Function Assessment Method: A Prospective, Multicenter, Double-Blind, Crossover Trial","Inclusion Criteria:\n\n* Ultrasound assessment identifies people with normal biliary tract structure.\n\nExclusion Criteria:\n\n* History of Endoscopic Retrograde Cholangiopancreatography\n* Previous gallstone removal surgery with gallbladder preservation\n* Other biliary tract diseases and related surgical history\n* History of acute or chronic pancreatitis\n* History of gastrointestinal surgery\n* Gastrointestinal obstruction\n* Dysfunction of the sphincter of Oddi\n* Gallbladder neck polyps\n* Abnormal gallbladder structure\n* Gallbladder mass\n* Biliary infection or stones\n* Congenital biliary abnormalities\n* Biliary injury or surgery\n* Biliary tumors\n* Gastrointestinal bleeding, liver cirrhosis, or other malignant diseases\n* Significant arrhythmia, bradycardia, or atrioventricular block\n* Severe hypertension, liver or kidney insufficiency\n* Immune, endocrine, hematological, or mental disorders\n* Severe cerebrovascular disease\n* Allergy to relevant foods\n* Pregnant or breastfeeding women\n* Unwillingness or inability to consent to participation",true,"ALL","18 Years","70 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a multicenter, prospective, randomized, double-blind, crossover study involving healthy individuals, aiming to evaluate the stability of oral protein bars + olive oil as a new method for determining gallbladder contraction function and its optimal diagnostic time window.",[28],"Gallbladder; Functional Disturbance",[30,31,32,33,34],"Gallbladder Contractile Function","Ultrasound Examination","Olive oil","Protein Bar","Optimal time","RECRUITING","2026-01-06",{"date":38,"type":39},"2026-01-08","ACTUAL",{"date":41,"type":39},"2026-01-07",{"date":43,"type":22},"2026-12-20",{"name":45,"class":46},"Hepatopancreatobiliary Surgery Institute of Gansu Province","OTHER",5,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100569806","a-strategy-for-gallstone-expulsion-through-dietary-therapy-100569806","NCT06699030","A Strategy for Gallstone Expulsion Through Dietary Therapy","A New Strategy for Gallstone Expulsion Through Dietary Therapy: A Prospective, Single-Center, Double-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Gallbladder sludge-like stones with a maximum stone diameter of less than 2 mm\n\nExclusion Criteria:\n\n* History of ERCP (Endoscopic Retrograde Cholangiopancreatography)\n* Previous gallstone removal surgery with gallbladder preservation\n* History of acute or chronic pancreatitis, cholangitis\n* Mirizzi Syndrome\n* History of gastrointestinal surgery\n* Gastrointestinal obstruction\n* Dysfunction of the sphincter of Oddi\n* Gallbladder neck polyps\n* Abnormal gallbladder structure\n* Gallbladder mass\n* Biliary infection or stones\n* Congenital biliary abnormalities\n* Biliary injury or surgery\n* Biliary tumors\n* Gastrointestinal bleeding, liver cirrhosis, or other malignant diseases\n* Significant arrhythmia, bradycardia, or atrioventricular block\n* Severe hypertension, liver or kidney insufficiency\n* Immune, endocrine, hematological, or mental disorders\n* Severe cerebrovascular disease\n* Allergy to relevant foods\n* Pregnant or breastfeeding women\n* Unwillingness or inability to consent to participation",{"count":56,"type":22},100,[25],"This study is a double-blind, prospective, single-center controlled trial conducted at a tertiary hospital, aiming to determine whether dietary therapy can effectively expel gallstones.",[60],"Gallbladder Stone",[62,63,64,31],"Gallstone","Gallbladder Function","Cholecystitis","2025-12-24",{"date":67,"type":39},"2025-12-31",{"date":69,"type":39},"2024-12-24",{"date":71,"type":22},"2026-12-01",{"name":45,"class":46},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100293799","effect-of-37-non-ionic-contrast-agent-during-ercp-procedure-in-hilar-cholangiocarcinoma-100293799","NCT03104569","Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma","Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma: A Prospective Double-blind Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n* Type Ⅰ、Ⅱ、Ⅲ、Ⅳ of Hilar Cholangiocarcinoma;\n* Age: 18\\~90 years old;\n* Underwent diagnostic and therapeutic ERCP;\n\nExclusion Criteria:\n\n* Coagulation dysfunction(INR\\>1.3) or\u002Fand low peripheral blood platelet count （PLT \\\u003C50x10\\^9\u002FL）;\n* Preoperative acute cholangitis;\n* Preoperative acute pancreatitis;\n* Preoperative hemobilia or hemorrhage of digestive tract;\n* Preoperative liver failure;\n* Combined with Mirizzi syndrome and intrahepatic bile duct stones;\n* Preoperative malignant tumor of biliary system such as carcinoma of head of pancreas, gallbladder carcinoma;\n* Biliary-duodenal fistula confirmed during ERCP;\n* A history of reconstructive surgery for upper digestive tract except Billroth Ⅰand a history of cholangioenterostomy including cholangio-jejunostomy and side to side anastomosis of the bile duct and duodenum;\n* Previous ERCP;\n* Pregnant women","90 Years",{"count":56,"type":22},[25],"The purpose of this study is to determine the effect of normal temperature and 37℃ non-ionic contrast agent acting on ERCP-related cholangeitis after endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of hilar cholangiocarcinoma.",[86],"Cholangitis",[88,89,90,86,91],"ERCP","Contrast agent","Hilar cholangiocarcinoma","Nonionic","NOT_YET_RECRUITING","2025-12-19",{"date":95,"type":39},"2025-12-26",{"date":97,"type":22},"2026-04-01",{"date":99,"type":22},"2028-12-01",{"name":45,"class":46},3,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":73},"100599979","whether-control-of-serum-uric-acid-sua-improves-survival-after-pancreatic-cancer-100599979","NCT07091526","Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer","Whether Controlling Serum Uric Acid (SUA) Can Benefit Postoperative Survival in Patients With Pancreatic Cancer","Inclusion Criteria:\n\n* Patients with pathologically confirmed pancreatic cancer (primary)\n* Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy）\n* The postoperative survival time was at least 6 weeks\n\nExclusion Criteria:\n\n* No surgery was performed, or only palliative surgery\u002F biopsy was performed\n* Patients who underwent emergency hemodialysis or plasma exchange after surgery\n* History of gout or long-term urate-lowering therapy, such as allopurinol\n* Patients are missing follow-up data\n* Hydrochlorothiazide and furosemide were used\n* Chronic kidney disease\n* Oncolytic syndrome\n* Hemolytic anemia\n* Lead poisoning\n* Hyperparathyroidism\n* Hypothyroidism\n* A tyrosinase inhibitor was used\n* Patients with nonpancreatic primary tumors\n* Pregnant or postpartum women.","85 Years",{"count":111,"type":22},168,"OBSERVATIONAL","This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.",[115],"Serum Uric Acid",[117,118,119,120],"Serum uric acid","Pancreatic cancer","Pancreaticoduodenectomy","Distal pancreatectomy","2025-12-13",{"date":93,"type":39},{"date":124,"type":39},"2025-07-29",{"date":126,"type":22},"2026-12-29",{"name":45,"class":46},""]